The University of California, San Francisco, and colleagues have conducted a study revealing that self-reported age at onset of hidradenitis suppurativa has a bimodal distribution, with peak common onset occurring in the late teens and peak late onset occurring in the mid-40s according to this retrospective study.
It is hoped that the findings will support more accurate and timely diagnosis of what is a very troubling condition reported Healio by author Julia Lowndes. The team published their findings in JAMA
The research team collected and analyzed data from 1,203 patients with a dermatologist -confirmed hidradenitis suppurativa (HS). The data included age at visit, self-reported age at onset, race, sex, self-identified ethnicity, and disease severity.
In this study, the UCSF-led team compared age at the onset across race, sex and disease severity using Wilcoxon tests, and Cullen-Fry plots for identification of age at onset as a log-normal distribution.
The team found that sex was significantly associated with onset age—so they used a mixture of regression with sex as a covariate to identify subpopulations. As mentioned previously, self-reported age at onset of hidradenitis suppurativa has a bimodal distribution, with peak common onset occurring in the late teens and peak late onset occurring in the mid-40s.
Median age at onset was earlier for females than males (19 vs. 23 years; P.001). Additionally, the age at common onset for females was materially earlier than for males (16.8 years vs. 19.7 years; P.001).
Hispanics report younger than Blacks & Whites
Hispanic patients had earlier onset ages (18.5 years) than blacks (20 years; P=.03) and whites (20 years; P=.02).
Lead Investigator and Comments
Dr. Haley B. Naik led the study and reported: “These findings may help facilitate accurate and timely diagnosis of HS in a previously unrecognized HS subpopulation.”
The research leads acknowledged that recall bias of self-reported age and variable disease duration could be studying limitations.
Dr. Haley B. Naik, Dermatologist, UCSF
It was disclosed that Dr. Naik has performed consulting work for 23andMe as well as served as a co-investigator on a grant from AbbVie. It should be noted that AbbVie is very active in marketing and distributing Humira to HS patients via physician and provider system channels.Source: Healio